{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Tumors&page=4", "query": { "condition": "Kidney Tumors", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1799, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Tumors&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Tumors&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:04:48.513Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03438708", "title": "Prior Axitinib as a Determinant of Outcome of Renal Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Axitinib Oral Tablet [Inlyta]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-03-05", "completion_date": "2026-03-04", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 2, "location_summary": "La Jolla, California • Cleveland, Ohio", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03438708" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT04977453", "title": "GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Cervical Cancer", "Urothelial Carcinoma", "Clear Cell Renal Cell Cancer (ccRCC)", "Squamous Cell Non Small Cell Lung Cancer" ], "interventions": [ { "name": "GI-101", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "GI-101A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2021-08-02", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 3, "location_summary": "New York, New York • Huntersville, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04977453" }, { "nct_id": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Head and Neck Cancer", "Breast Cancer", "Colon Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Prostate Cancer", "Uterine Cancer", "Cervix Cancer", "Ovarian Cancer", "Kidney Cancer", "Bladder Cancer", "Thyroid Cancer", "Melanoma", "Sarcoma", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "SNS-101 (anti-VISTA)", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sensei Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-05-31", "completion_date": "2026-06-02", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05864144" }, { "nct_id": "NCT00333502", "title": "Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor" ], "interventions": [ { "name": "Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2006-05", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Duarte, California • Farmington, New Mexico", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Farmington", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333502" }, { "nct_id": "NCT02419495", "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Fallopian Tube Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Ovarian Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Primary Peritoneal Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Melanoma", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-06-26", "completion_date": "2024-09-16", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 5, "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more", "locations": [ { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "League City", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419495" }, { "nct_id": "NCT06456411", "title": "Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma", "Kidney Carcinoma", "Carcinoma" ], "interventions": [ { "name": "Functional Near-Infrared Spectroscopy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Virtual Technology Intervention", "type": "OTHER" }, { "name": "Cold Stimulation", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2022-07-12", "completion_date": "2026-04-10", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06456411" }, { "nct_id": "NCT02542202", "title": "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Renal Cell Cancer", "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-05-01", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542202" }, { "nct_id": "NCT07397611", "title": "Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma", "Kidney Cancer", "Kidney Neoplasm", "Renal Carcinoma" ], "interventions": [ { "name": "Casdatifan", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-03-09", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07397611" }, { "nct_id": "NCT02440334", "title": "Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Optison", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2015-04-23", "completion_date": "2018-06-21", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-11-15T12:04:48.513Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02440334" } ] }